{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T23:05:05Z","timestamp":1790636705978,"version":"4.1.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":20,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008732","name":"Uehara Memorial Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008732","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100032701","name":"Bavarian State Ministry of Health, Care and Prevention","doi-asserted-by":"crossref","award":["DigiMed Bayern"],"award-info":[{"award-number":["DigiMed Bayern"]}],"id":[{"id":"10.13039\/100032701","id-type":"DOI","asserted-by":"crossref"}]},{"name":"German Federal Ministry of Education and Research","award":["DZD"],"award-info":[{"award-number":["DZD"]}]},{"name":"German Federal Ministry of Education and Research","award":["KORA"],"award-info":[{"award-number":["KORA"]}]},{"name":"Innovative Medicines Initiative 2","award":["No. 821508 (CARDIATEAM)"],"award-info":[{"award-number":["No. 821508 (CARDIATEAM)"]}]},{"name":"Helmholtz Zentrum M\u00fcnchen - Deutsches Forschungszentrum f\u00fcr Gesundheit und Umwelt (GmbH)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sodium-glucose co-transporter 2 inhibitors (SGLT2i), when combined with metformin (COMBI), offer multi-organ protective effects in patients with type 2 diabetes (T2D), particularly those at high risk of cardiovascular or renal complications. However, the underlying molecular mechanisms remain poorly understood.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We profiled 303 targeted serum metabolites in 1494 participants of the KORA study, including T2D patients treated with COMBI therapy, metformin monotherapy, or no glucose-lowering medication. Additionally, metabolomic profiling was quantified on seven tissues (plasma, liver, adrenal glands, adipose tissue, testis, lung, and cerebellum), and related hepatic transcripts were evaluated in 40 mice. Multivariable linear regression analyses, adjusted for age, sex, BMI, lifestyle, glycemic, and cardiovascular risk factors, were applied to human data; tissue-specific regression analyses were conducted for murine samples. Identified metabolites were further investigated using biochemical pathway analyses and literature review.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      COMBI therapy was associated with significant changes in metabolite profiles. In humans, 10 metabolites were significantly altered compared to metformin monotherapy. In mice, 82 altered metabolites were identified in plasma, 52 in liver, 30 in adrenal glands, 12 in adipose tissue, seven in testis, seven in lung, and six in cerebellum. COMBI therapy lowered threonine concentrations in both human serum and murine plasma but raised threonine, glycine, and urea cycle metabolites (citrulline, asymmetric dimethyl arginine (ADMA), and ornithine) in murine liver. This was accompanied by enhanced hepatic expression of\n                      <jats:italic>Slc38a2,<\/jats:italic>\n                      a threonine transporter gene. In humans, urea cycle metabolites correlated strongly with the fibrosis-4 index, a marker of liver fibrosis. Additionally, COMBI therapy elevated ketone body markers, such as hydroxybutyrylcarnitine, across murine liver, plasma, adrenal glands, adipose tissue, and testis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>COMBI therapy modulates amino acid metabolism, the urea cycle, and ketone body production, suggesting potential mechanisms underlying its protective effects against liver fibrosis and male subfertility. These findings provide novel insights into the systemic metabolic actions of COMBI therapy and highlight its translational potential to improve clinical outcomes in T2D patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12916-025-04609-7","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T02:25:30Z","timestamp":1767839130000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Urea cycle modulation by combined SGLT2 inhibitors and metformin"],"prefix":"10.1186","volume":"24","author":[{"given":"Makoto","family":"Harada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Adam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyu","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengya","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhong","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jutta","family":"Lintelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Cecil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Zukunft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"Prehn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Witting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus F.","family":"Scheerer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Neschen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Irmler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Beckers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerzy","family":"Adamski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Teupser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Linkohr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Gieger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin Hrab\u011b","family":"de Angelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Wang-Sattler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"key":"4609_CR1","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41586-019-1797-8","volume":"576","author":"M Roden","year":"2019","unstructured":"Roden M, Shulman GI. The integrative biology of type 2 diabetes. Nature. 2019;576:51\u201360.","journal-title":"Nature"},{"key":"4609_CR2","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.2337\/dci22-0034","volume":"45","author":"MJ Davies","year":"2022","unstructured":"Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45:2753\u201386.","journal-title":"Diabetes Care"},{"key":"4609_CR3","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1001\/jamacardio.2023.1266","volume":"8","author":"JB Pierce","year":"2023","unstructured":"Pierce JB, Vaduganathan M, Fonarow GC, Ikeaba U, Chiswell K, Butler J, et al. Contemporary Use of Sodium-Glucose Cotransporter-2 Inhibitor Therapy Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction in the US: The Get With The Guidelines-Heart Failure Registry. JAMA Cardiol. 2023;8:652\u201361.","journal-title":"JAMA Cardiol"},{"key":"4609_CR4","doi-asserted-by":"publisher","first-page":"284","DOI":"10.2337\/db14-0393","volume":"64","author":"S Neschen","year":"2015","unstructured":"Neschen S, Scheerer M, Seelig A, Huypens P, Schultheiss J, Wu M, et al. Metformin supports the antidiabetic effect of a sodium glucose cotransporter 2 inhibitor by suppressing endogenous glucose production in diabetic mice. Diabetes. 2015;64:284\u201390.","journal-title":"Diabetes"},{"key":"4609_CR5","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.diabet.2018.09.005","volume":"44","author":"F Bonnet","year":"2018","unstructured":"Bonnet F, Scheen AJ. Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: the potential contribution to diabetes complications and cardiovascular disease. Diabetes Metab. 2018;44:457\u201364.","journal-title":"Diabetes Metab"},{"key":"4609_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-52603-5","volume":"14","author":"AMC Ong Lopez","year":"2024","unstructured":"Ong Lopez AMC, Pajimna JAT. Efficacy of sodium glucose cotransporter 2 inhibitors on hepatic fibrosis and steatosis in non-alcoholic fatty liver disease: an updated systematic review and meta-analysis. Sci Rep. 2024;14:2122.","journal-title":"Sci Rep"},{"key":"4609_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0305636","volume":"19","author":"R Bdeir","year":"2024","unstructured":"Bdeir R, Al-Sawalha NA, Al-Fawares O, Hamadeneh L, Khawaldeh A. Effects of empagliflozin on gonadal functions of hyperglycemic male wistar rats. PLoS ONE. 2024;19:e0305636.","journal-title":"PLoS ONE"},{"key":"4609_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22147684","volume":"22","author":"A Lymperopoulos","year":"2021","unstructured":"Lymperopoulos A, Borges JI, Cora N, Sizova A. Sympatholytic mechanisms for the beneficial cardiovascular effects of SGLT2 inhibitors: a research hypothesis for dapagliflozin\u2019s effects in the adrenal gland. Int J Mol Sci. 2021;22:7684.","journal-title":"Int J Mol Sci"},{"key":"4609_CR9","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/nature10354","volume":"477","author":"K Suhre","year":"2011","unstructured":"Suhre K, Shin S-Y, Petersen A-K, Mohney RP, Meredith D, W\u00e4gele B, et al. Human metabolic individuality in biomedical and pharmaceutical research. Nature. 2011;477:54\u201360.","journal-title":"Nature"},{"key":"4609_CR10","doi-asserted-by":"publisher","first-page":"3776","DOI":"10.2337\/db16-0512","volume":"65","author":"J Adam","year":"2016","unstructured":"Adam J, Brandmaier S, Leonhardt J, Scheerer MF, Mohney RP, Xu T, et al. Metformin Effect on Nontargeted Metabolite Profiles in Patients With Type 2 Diabetes and in Multiple Murine Tissues. Diabetes. 2016;65:3776\u201385.","journal-title":"Diabetes"},{"issue":"Pt 1","key":"4609_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2024.130962","volume":"265","author":"M Harada","year":"2024","unstructured":"Harada M, Han S, Shi M, Ge J, Yu S, Adam J, et al. Metabolic effects of SGLT2i and metformin on 3-hydroxybutyric acid and lactate in db\/db mice. Int J Biol Macromol. 2024;265(Pt 1):130962.","journal-title":"Int J Biol Macromol"},{"key":"4609_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-024-02288-x","volume":"23","author":"M Harada","year":"2024","unstructured":"Harada M, Adam J, Covic M, Ge J, Brandmaier S, Muschet C, et al. Bidirectional modulation of TCA cycle metabolites and anaplerosis by metformin and its combination with SGLT2i. Cardiovasc Diabetol. 2024;23:199.","journal-title":"Cardiovasc Diabetol"},{"key":"4609_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/metabo13050648","volume":"13","author":"B Amer","year":"2023","unstructured":"Amer B, Deshpande RR, Bird SS. Simultaneous quantitation and discovery (SQUAD) analysis: combining the best of targeted and untargeted mass spectrometry-based metabolomics. Metabolites. 2023;13:648.","journal-title":"Metabolites"},{"key":"4609_CR14","doi-asserted-by":"publisher","first-page":"5426","DOI":"10.1002\/anie.200905579","volume":"49","author":"WJ Griffiths","year":"2010","unstructured":"Griffiths WJ, Koal T, Wang Y, Kohl M, Enot DP, Deigner H-P. Targeted metabolomics for biomarker discovery. Angew Chem Int Ed Engl. 2010;49:5426\u201345.","journal-title":"Angew Chem Int Ed Engl"},{"key":"4609_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0207082","volume":"13","author":"A Ribbenstedt","year":"2018","unstructured":"Ribbenstedt A, Ziarrusta H, Benskin JP. Development, characterization and comparisons of targeted and non-targeted metabolomics methods. PLoS One. 2018;13:e0207082.","journal-title":"PLoS One"},{"key":"4609_CR16","doi-asserted-by":"publisher","unstructured":"Diabetes Care. 2025:dc251707. https:\/\/doi.org\/10.2337\/dc25-1707. Online ahead of print. PMID: 41335123","DOI":"10.2337\/dc25-1707"},{"key":"4609_CR17","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/msb.2012.43","volume":"8","author":"R Wang-Sattler","year":"2012","unstructured":"Wang-Sattler R, Yu Z, Herder C, Messias AC, Floegel A, He Y, et al. Novel biomarkers for pre-diabetes identified by metabolomics. Mol Syst Biol. 2012;8:615.","journal-title":"Mol Syst Biol"},{"key":"4609_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/metabo11020089","volume":"11","author":"J Huang","year":"2021","unstructured":"Huang J, Covic M, Huth C, Rommel M, Adam J, Zukunft S, et al. Validation of candidate phospholipid biomarkers of chronic kidney disease in hyperglycemic individuals and their organ-specific exploration in leptin receptor-deficient db\/db mouse. Metabolites. 2021;11:89.","journal-title":"Metabolites"},{"key":"4609_CR19","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyaf187","volume":"54","author":"B Linkohr","year":"2025","unstructured":"Linkohr B, Heier M, Gieger C, Thorand B, Grallert H, Holle R, et al. Cohort profile: cooperative health research in the region of Augsburg (KORA) 1984-2024. Int J Epidemiol. 2025;54:dyaf187.","journal-title":"Int J Epidemiol"},{"key":"4609_CR20","first-page":"574","volume":"58","author":"M Bickel","year":"2008","unstructured":"Bickel M, Brummerhop H, Frick W, Glombik H, Herling AW, Heuer HO, et al. Effects of AVE2268, a substituted glycopyranoside, on urinary glucose excretion and blood glucose in mice and rats. Arzneimittelforschung. 2008;58:574\u201380.","journal-title":"Arzneimittelforschung"},{"key":"4609_CR21","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1021\/acs.jproteome.7b00518","volume":"17","author":"M Haid","year":"2018","unstructured":"Haid M, Muschet C, Wahl S, R\u00f6misch-Margl W, Prehn C, M\u00f6ller G, et al. Long-term stability of human plasma metabolites during storage at -80 \u00b0C. J Proteome Res. 2018;17:203\u201311.","journal-title":"J Proteome Res"},{"key":"4609_CR22","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbab535","volume":"23","author":"S Han","year":"2022","unstructured":"Han S, Huang J, Foppiano F, Prehn C, Adamski J, Suhre K, et al. TIGER: technical variation elimination for metabolomics data using ensemble learning architecture. Brief Bioinform. 2022;23:bbab535.","journal-title":"Brief Bioinform"},{"key":"4609_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1005973","volume":"14","author":"R Wei","year":"2018","unstructured":"Wei R, Wang J, Jia E, Chen T, Ni Y, Jia W. GSimp: a gibbs sampler based left-censored missing value imputation approach for metabolomics studies. PLoS Comput Biol. 2018;14:e1005973.","journal-title":"PLoS Comput Biol"},{"key":"4609_CR24","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s11306-017-1312-x","volume":"14","author":"S Zukunft","year":"2018","unstructured":"Zukunft S, Prehn C, R\u00f6hring C, M\u00f6ller G, Hrab\u011b de Angelis M, Adamski J, et al. High-throughput extraction and quantification method for targeted metabolomics in murine tissues. Metabolomics. 2018;14:18.","journal-title":"Metabolomics."},{"key":"4609_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v045.i03","volume":"45","author":"S Buuren","year":"2011","unstructured":"Buuren S, Groothuis-Oudshoorn K. Mice: multivariate imputation by chained equations in R. J Stat Softw. 2011;45:1\u201367.","journal-title":"J Stat Softw"},{"key":"4609_CR26","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkt090","volume":"41","author":"TJ Triche Jr","year":"2013","unstructured":"Triche TJ Jr, Weisenberger DJ, Van Den Berg D, Laird PW, Siegmund KD. Low-level processing of Illumina Infinium DNA methylation BeadArrays. Nucleic Acids Res. 2013;41:e90.","journal-title":"Nucleic Acids Res"},{"issue":"Web Server issu","key":"4609_CR27","doi-asserted-by":"publisher","first-page":"W498","DOI":"10.1093\/nar\/gkl038","volume":"34","author":"J Rainer","year":"2006","unstructured":"Rainer J, Sanchez-Cabo F, Stocker G, Sturn A, Trajanoski Z. CARMAweb: comprehensive R- and bioconductor-based web service for microarray data analysis. Nucleic Acids Res. 2006;34(Web Server issue):W498-503.","journal-title":"Nucleic Acids Res."},{"key":"4609_CR28","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1093\/bioinformatics\/btp040","volume":"25","author":"Y Xie","year":"2009","unstructured":"Xie Y, Wang X, Story M. Statistical methods of background correction for Illumina BeadArray data. Bioinformatics. 2009;25:751\u20137.","journal-title":"Bioinformatics"},{"key":"4609_CR29","doi-asserted-by":"publisher","unstructured":"Cheuk-Fung Yip T, Lee HW, Lin H, Tsochatzis E, Petta S, Bugianesi E, et al. Prognostic performance of the two-step clinical care pathway in metabolic dysfunction-associated steatotic liver disease. J Hepatol. 2025;83(2):304\u201314. https:\/\/doi.org\/10.1016\/j.jhep.2025.01.014. Epub 2025 Jan 23. PMID: 39863175","DOI":"10.1016\/j.jhep.2025.01.014"},{"key":"4609_CR30","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1371\/journal.pgen.0030161","volume":"3","author":"JT Leek","year":"2007","unstructured":"Leek JT, Storey JD. Capturing heterogeneity in gene expression studies by surrogate variable analysis. PLoS Genet. 2007;3:1724\u201335.","journal-title":"PLoS Genet"},{"key":"4609_CR31","unstructured":"R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria. R Foundation for Statistical Computing. 2009."},{"key":"4609_CR32","doi-asserted-by":"publisher","first-page":"D521","DOI":"10.1093\/nar\/gkl923","volume":"35 Database iss","author":"DS Wishart","year":"2007","unstructured":"Wishart DS, Tzur D, Knox C, Eisner R, Guo AC, Young N, et al. HMDB: the Human Metabolome Database. Nucleic Acids Res. 2007;35 Database issue:D521-526.","journal-title":"Nucleic Acids Res."},{"key":"4609_CR33","doi-asserted-by":"crossref","unstructured":"Kanehisa M, Goto S, Sato Y, Kawashima M, Furumichi M, Tanabe M. Data, information, knowledge and principle: back to metabolism in KEGG. Nucleic Acids Res. 2014;42 Database issue:D199\u2013205.","DOI":"10.1093\/nar\/gkt1076"},{"key":"4609_CR34","doi-asserted-by":"publisher","first-page":"E877","DOI":"10.1152\/ajpendo.2000.278.5.E877","volume":"278","author":"PB Darling","year":"2000","unstructured":"Darling PB, Grunow J, Rafii M, Brookes S, Ball RO, Pencharz PB. Threonine dehydrogenase is a minor degradative pathway of threonine catabolism in adult humans. Am J Physiol Endocrinol Metab. 2000;278:E877-884.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"4609_CR35","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1038\/s10038-019-0614-4","volume":"64","author":"S Matsumoto","year":"2019","unstructured":"Matsumoto S, H\u00e4berle J, Kido J, Mitsubuchi H, Endo F, Nakamura K. Urea cycle disorders-update. J Hum Genet. 2019;64:833\u201347.","journal-title":"J Hum Genet"},{"key":"4609_CR36","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/s41586-019-0996-7","volume":"567","author":"L Li","year":"2019","unstructured":"Li L, Mao Y, Zhao L, Li L, Wu J, Zhao M, et al. P53 regulation of ammonia metabolism through urea cycle controls polyamine biosynthesis. Nature. 2019;567:253\u20136.","journal-title":"Nature"},{"key":"4609_CR37","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1038\/s41575-024-00970-9","volume":"21","author":"R Gallego-Dur\u00e1n","year":"2024","unstructured":"Gallego-Dur\u00e1n R, Hadjihambi A, Ampuero J, Rose CF, Jalan R, Romero-G\u00f3mez M. Ammonia-induced stress response in liver disease progression and hepatic encephalopathy. Nat Rev Gastroenterol Hepatol. 2024;21:774\u201391.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"4609_CR38","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s42255-020-0199-4","volume":"2","author":"A Fu","year":"2020","unstructured":"Fu A, Alvarez-Perez JC, Avizonis D, Kin T, Ficarro SB, Choi DW, et al. Glucose-dependent partitioning of arginine to the urea cycle protects \u03b2-cells from inflammation. Nat Metab. 2020;2:432\u201346.","journal-title":"Nat Metab"},{"key":"4609_CR39","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1016\/j.cmet.2024.07.007","volume":"36","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Higgins CB, Tica S, Adams JA, Sun J, Kelly SC, et al. Hierarchical tricarboxylic acid cycle regulation by hepatocyte arginase 2 links the urea cycle to oxidative metabolism. Cell Metab. 2024;36:2069-2085.e8.","journal-title":"Cell Metab"},{"key":"4609_CR40","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1016\/j.metabol.2011.11.009","volume":"61","author":"MR Soeters","year":"2012","unstructured":"Soeters MR, Serlie MJ, Sauerwein HP, Duran M, Ruiter JP, Kulik W, et al. Characterization of D-3-hydroxybutyrylcarnitine (ketocarnitine): an identified ketosis-induced metabolite. Metabolism. 2012;61:966\u201373.","journal-title":"Metabolism"},{"key":"4609_CR41","doi-asserted-by":"publisher","first-page":"8030","DOI":"10.1073\/pnas.1016088108","volume":"108","author":"I Kimura","year":"2011","unstructured":"Kimura I, Inoue D, Maeda T, Hara T, Ichimura A, Miyauchi S, et al. Short-chain fatty acids and ketones directly regulate sympathetic nervous system via G protein-coupled receptor 41 (GPR41). Proc Natl Acad Sci U S A. 2011;108:8030\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4609_CR42","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1113\/EP085146","volume":"101","author":"MJ Joyner","year":"2016","unstructured":"Joyner MJ, Wallin BG, Charkoudian N. Sex differences and blood pressure regulation in humans. Exp Physiol. 2016;101:349\u201355.","journal-title":"Exp Physiol"},{"key":"4609_CR43","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1016\/0735-1097(92)90256-M","volume":"20","author":"DJ Mariano","year":"1992","unstructured":"Mariano DJ, Schomer SJ, Rea RF. Effects of quinidine on vascular resistance and sympathetic nerve activity in humans. J Am Coll Cardiol. 1992;20:1411\u20136.","journal-title":"J Am Coll Cardiol"},{"key":"4609_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-021-02185-0","volume":"19","author":"H Kolb","year":"2021","unstructured":"Kolb H, Kempf K, R\u00f6hling M, Lenzen-Schulte M, Schloot NC, Martin S. Ketone bodies: from enemy to friend and guardian angel. BMC Med. 2021;19:313.","journal-title":"BMC Med"},{"key":"4609_CR45","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s11255-009-9565-6","volume":"41","author":"A Bener","year":"2009","unstructured":"Bener A, Al-Ansari AA, Zirie M, Al-Hamaq AOAA. Is male fertility associated with type 2 diabetes mellitus? Int Urol Nephrol. 2009;41:777\u201384.","journal-title":"Int Urol Nephrol"},{"key":"4609_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1279058","volume":"14","author":"X-B Zhu","year":"2023","unstructured":"Zhu X-B, Niu Z-H, Fan W-M, Sheng C-S, Chen Q. Type 2 diabetes mellitus and the risk of male infertility: a Mendelian randomization study. Front Endocrinol (Lausanne). 2023;14:1279058.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"4609_CR47","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/nm.3804","volume":"21","author":"Y-H Youm","year":"2015","unstructured":"Youm Y-H, Nguyen KY, Grant RW, Goldberg EL, Bodogai M, Kim D, et al. The ketone metabolite \u03b2-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat Med. 2015;21:263\u20139.","journal-title":"Nat Med"},{"key":"4609_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/antiox7050063","volume":"7","author":"A Pinto","year":"2018","unstructured":"Pinto A, Bonucci A, Maggi E, Corsi M, Businaro R. Anti-oxidant and anti-inflammatory activity of ketogenic diet: new perspectives for neuroprotection in Alzheimer\u2019s disease. Antioxidants (Basel). 2018;7:63.","journal-title":"Antioxidants (Basel)"},{"key":"4609_CR49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0021230","volume":"6","author":"Z Yu","year":"2011","unstructured":"Yu Z, Kastenm\u00fcller G, He Y, Belcredi P, M\u00f6ller G, Prehn C, et al. Differences between human plasma and serum metabolite profiles. PLoS One. 2011;6:e21230.","journal-title":"PLoS One"},{"key":"4609_CR50","doi-asserted-by":"publisher","first-page":"140","DOI":"10.2337\/dc23-1163","volume":"47","author":"MM Umapathysivam","year":"2024","unstructured":"Umapathysivam MM, Gunton J, Stranks SN, Jesudason D. Euglycemic ketoacidosis in two patients without diabetes after introduction of sodium-glucose cotransporter 2 inhibitor for heart failure with reduced ejection fraction. Diabetes Care. 2024;47:140\u20133.","journal-title":"Diabetes Care"},{"key":"4609_CR51","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2023-003666","volume":"11","author":"E Chow","year":"2023","unstructured":"Chow E, Clement S, Garg R. Euglycemic diabetic ketoacidosis in the era of SGLT-2 inhibitors. BMJ Open Diabetes Res Care. 2023;11:e003666.","journal-title":"BMJ Open Diabetes Res Care"},{"key":"4609_CR52","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1002\/jat.4329","volume":"42","author":"JA Phillips","year":"2022","unstructured":"Phillips JA, Taub ME, Bogdanffy MS, Yuan J, Knight B, Smith JD, et al. Mode of action and human relevance assessment of male CD-1 mouse renal adenocarcinoma associated with lifetime exposure to empagliflozin. J Appl Toxicol. 2022;42:1570\u201384.","journal-title":"J Appl Toxicol"},{"key":"4609_CR53","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1124\/dmd.109.029165","volume":"38","author":"M Obermeier","year":"2010","unstructured":"Obermeier M, Yao M, Khanna A, Koplowitz B, Zhu M, Li W, et al. In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans. Drug Metab Dispos. 2010;38:405\u201314.","journal-title":"Drug Metab Dispos"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-025-04609-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-04609-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-04609-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T13:05:55Z","timestamp":1769605555000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12916-025-04609-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4609"],"URL":"https:\/\/doi.org\/10.1186\/s12916-025-04609-7","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,8]]},"assertion":[{"value":"18 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The KORA-Fit study protocols were approved by the Ethics Committees of the Bavarian Chamber of Physicians (KORA-Fit EC No. 17040) and were conducted in accordance with the Declaration of Helsinki. All participants provided written informed consent.The mouse experiments were approved by the Government of Upper Bavaria (approval numbers: Gz.55.2\u20131-54\u20132531-70\u201307, 55.2\u20131-2532\u2013153-11).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. The manuscript contains no data that could identify any individual participant; hence, consent for publication is not necessary.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Markus F. Scheerer was employed at Helmholtz Zentrum M\u00fcnchen during his PhD thesis and was recently employed in the CardioRenal Medical Department of Bayer AG, however, the company was not involved in work related to data and manuscript generation. Susanne Neschen was employed by the Helmholtz Zentrum M\u00fcnchen during the execution of this study. She is currently an employee of Sanofi Aventis Deutschland GmbH. However, this company was not involved in work related to data and manuscript generation.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"55"}}